Bristol Myers announced the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, has recommended marketing authorization approval of Abecma for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies, including an immunomodulatory agent, or IMiD, a proteasome inhibitor, or PI, and an anti-CD38 monoclonal antibody. The European Commission, or EC, which has the authority to approve medicines for the European Union, or EU, will now review the CHMP recommendation.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BMY:
- Bristol Myers completes acquisition of Mirati Therapeutics
- Bristol Myers, Exelixis announce four-year results from Opdivo-Cabometyx trial
- FDA instructs drugmakers to add T cell malignancy risk info to CAR-T labels
- Bristol Myers announces results from Phase 3 CheckMate -8HW trial
- Bristol Myers sees low to mid single digit revenue CAGR 2020-2025
